Literature DB >> 24673642

Busting robustness: using cancer's greatest strength to our advantage.

Jason R Westin1.   

Abstract

What do complex networks, such as those found in cancer cells, airplane flight patterns and the Internet have in common? A remarkable robustness with a surprising vulnerability. Complex networks follow remarkably similar patterns across seemingly unconnected fields, and it is possible that cancer researchers could thus learn from the advances in complex network theory. Very limited, yet coordinated, specific targeting of the most critical parts of a network can have dramatically outsized effects. "At times, our strengths propel us so far forward we can no longer endure our weaknesses and perish from them." Nietzsche.

Entities:  

Keywords:  cancer; combination therapy; complexity; robustness; scale free networks; small molecule inhibitors; targeted therapy

Mesh:

Year:  2015        PMID: 24673642     DOI: 10.2217/fon.14.49

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  5 in total

Review 1.  Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.

Authors:  Joyce Liu; Shannon N Westin
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

Review 2.  The rise of genomic profiling in ovarian cancer.

Authors:  Rebecca A Previs; Anil K Sood; Gordon B Mills; Shannon N Westin
Journal:  Expert Rev Mol Diagn       Date:  2016-12       Impact factor: 5.225

Review 3.  Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma.

Authors:  Francisco Azuaje; Katja Tiemann; Simone P Niclou
Journal:  Cell Commun Signal       Date:  2015-03-31       Impact factor: 5.712

4.  Cancer network activity associated with therapeutic response and synergism.

Authors:  Jordi Serra-Musach; Francesca Mateo; Eva Capdevila-Busquets; Gorka Ruiz de Garibay; Xiaohu Zhang; Raj Guha; Craig J Thomas; Judit Grueso; Alberto Villanueva; Samira Jaeger; Holger Heyn; Miguel Vizoso; Hector Pérez; Alex Cordero; Eva Gonzalez-Suarez; Manel Esteller; Gema Moreno-Bueno; Andreas Tjärnberg; Conxi Lázaro; Violeta Serra; Joaquín Arribas; Mikael Benson; Mika Gustafsson; Marc Ferrer; Patrick Aloy; Miquel Àngel Pujana
Journal:  Genome Med       Date:  2016-08-24       Impact factor: 11.117

Review 5.  Rational Combinations of Targeted Agents in AML.

Authors:  Prithviraj Bose; Steven Grant
Journal:  J Clin Med       Date:  2015-04-10       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.